Clinical Trial

A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I

Name: A Phase I/II Clinical Study to Evaluate SKG0201 Injection in Subjects With Spinal Muscular Atrophy Type I — clinical trial record (NCT07554924)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a phase I/II clinical study to evaluate the safety, preliminary efficacy and immunogenicity of SKG0201 injection in subjects with Spinal Muscular Atrophy Type I.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-04-21.

Trial Details

NCT Number	NCT07554924
Lead Sponsor	Lanyue Biotech (Hangzhou) Co., Ltd.
Conditions	Spinal Muscular Atrophy 1
Enrollment	11 participants
Start Date	2026-05-15
Primary Completion	2029-05-25 (estimated)
Study Completion	2029-05-25 (estimated)
Updated on ClinicalTrials.gov	2026-06-08